Abbott Laboratories $ABT Holdings Raised by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC boosted its stake in Abbott Laboratories (NYSE:ABT) by 46.7% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 350,431 shares of the healthcare product maker’s stock after buying an additional 111,573 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Abbott Laboratories were worth $47,662,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of ABT. Hughes Financial Services LLC bought a new position in shares of Abbott Laboratories during the 1st quarter valued at $27,000. Abound Financial LLC bought a new position in shares of Abbott Laboratories during the 1st quarter valued at $28,000. Elequin Capital LP bought a new position in shares of Abbott Laboratories during the 1st quarter valued at $30,000. JCIC Asset Management Inc. bought a new position in shares of Abbott Laboratories during the 1st quarter valued at $32,000. Finally, Vision Financial Markets LLC bought a new position in shares of Abbott Laboratories during the 1st quarter valued at $33,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

NYSE ABT opened at $132.30 on Monday. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The firm has a market capitalization of $230.26 billion, a price-to-earnings ratio of 16.58, a P/E/G ratio of 2.51 and a beta of 0.69. The company’s fifty day moving average is $132.54 and its two-hundred day moving average is $131.60. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. During the same period in the previous year, the business earned $1.14 EPS. The firm’s revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be given a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories’s payout ratio is 29.57%.

Insider Buying and Selling at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.46% of the company’s stock.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of recent research reports. Evercore ISI raised their price target on shares of Abbott Laboratories from $140.00 to $144.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. Leerink Partners initiated coverage on shares of Abbott Laboratories in a report on Monday, June 16th. They issued a “market perform” rating and a $143.00 target price on the stock. Raymond James Financial dropped their target price on shares of Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating on the stock in a report on Friday, July 18th. William Blair upgraded shares of Abbott Laboratories to a “strong-buy” rating in a report on Thursday, July 17th. Finally, The Goldman Sachs Group lifted their target price on shares of Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a report on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $146.17.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.